Mild Cognitive Impairment in Parkinson’s Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255–63.
Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.
Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–22.
Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol. 2007;254(1):38–45.
Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–707. quiz 837.
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–18.
Petersen RC. Challenges of epidemiological studies of mild cognitive impairment. Alzheimer Dis Assoc Disord. 2004;18(1):1–2.
Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127(Pt 3):550–60.
Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239–45.
• Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9(12):1200–13. This is a detailed and scholarly review of the variety of cognitive domains that are impaired in PD and their biological underpinnings.
•• Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009;72(13):1121–6. This is the first study describing the frequency of MCI in an incidence cohort of nearly 200 non-medicated PD patients.
• Elgh E, Domellof M, Linder J, et al. Cognitive function in early Parkinson’s disease: a population-based study. Eur J Neurol. 2009;16(12):1278–84. The authors report the frequency of MCI in 88 incident PD patients, most of them without medication, based on a comprehensive neuropsychological evaluation.
• Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–9. This is an international multicenter pooled analysis of more than 1300 non-demented PD patients from eight cohorts in the United States and Europe. A common MCI classification is applied to all subjects.
•• Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol. 2008;115(4):409–15. This is a carefully designed and skillfully conducted clinicopathologic study of the pathology underlying dementia in PD. The long-term prospective design allows for the identification of clinically relevant subgroups.
• Adler CH, Caviness JN, Sabbagh MN, et al. Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol. 2010;120(6):827–8. This is the first study describing the pathology of PD patients with MCI based on prospective and detailed cognitive assessment.
Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry. 2007;78(3):254–9.
Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson’s disease with and without dementia. Mov Disord. 2010;25(6):687–8.
• Dalaker TO, Larsen JP, Dwyer MG, et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson’s disease. Neuroimage. 2009;47(4):2083–9. This paper describes MRI findings in de novo PD patients with MCI. The small sample size led to relatively low statistical power.
• Dalaker TO, Zivadinov R, Larsen JP, et al. Gray matter correlations of cognition in incident Parkinson’s disease. Mov Disord. 2010;25(5):629–33. This paper also describes MRI findings in de novo PD patients with MCI. The small sample size led to relatively low statistical power.
• Dalaker TO, Larsen JP, Bergsland N, et al. Brain atrophy and white matter hyperintensities in early Parkinson’s disease(a). Mov Disord. 2009;24(15):2233–41. This paper also describes MRI findings in de novo PD patients with MCI. The small sample size led to relatively low statistical power.
Grambaite R, Reinvang I, Selnes P, et al. Pre-dementia memory impairment is associated with white matter tract affection. J Int Neuropsychol Soc. 2011;17(1):143–53.
Unger MM, Belke M, Menzler K, et al. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep. 2010;33(6):767–73.
Lee JE, Park HJ, Park B, et al. A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson’s disease dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2010;81(3):320–6.
Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage. 2007;34(2):714–23.
• Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord. 2010;25(15):2516–23. This is one of the first studies describing amyloid imaging in patients with prospectively classified PD-MCI based on neuropsychological assessment.
Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson’s disease dementia. Neuroimage. 2008;39(3):1027–33.
Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79(12):1331–8.
Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dement Geriatr Cogn Disord. 2006;22(3):200–8.
• Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010;81(10):1080–6. This community-based study is one of the first studies describing CSF protein changes in de novo PD and relating it to carefully defined MCI.
•• Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055–61. This study for the first time explores longitudinally the predictive power of CSF Alzheimer markers on cognitive impairment in non-demented PD.
Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213(2):315–25.
Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett. 2009;450(3):332–5.
Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010;133(Pt 3):713–26.
• Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75(20):1766–72. Although not specifically studying MCI, the authors have performed an interesting study measuring α-synuclein oligomers in CSF, a potential predictor of cognitive impairment and dementia in PD.
•• Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133(Pt 6):1747–54. This carefully designed study is among the first to suggest a possible cholinergic deficit related to olfactory dysfunction, a very early marker of PD, and cognitive functioning in non-demented PD patients.
Kehagia AA, Murray GK, Robbins TW. Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr Opin Neurobiol. 2010;20(2):199–204.
Whittington CJ, Podd J, Stewart-Williams S. Memory deficits in Parkinson’s disease. J Clin Exp Neuropsychol. 2006;28(5):738–54.
• Bronnick K, Alves G, Aarsland D, et al. Verbal memory in drug-naive, newly diagnosed Parkinson’s disease. The retrieval deficit hypothesis revisited. Neuropsychology. 2010;25(1):114–24. This is one of the most detailed studies of memory functioning in nearly 200 de novo PD patients.
Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of the cognitive and behavioral sequelae of Parkinson’s disease: relationship to frontostriatal circuitry. Cogn Behav Neurol. 2003;16(4):193–210.
Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson’s disease. Mov Disord. 2007;22(9):1272–7.
• Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord. 2009;24(8):1103–10. The authors carefully compare the strengths and limitations of various cognitive screening scales for use in patients with PD.
Muslimovic D, Schmand B, Speelman JD, de Haan RJ. Course of cognitive decline in Parkinson’s disease: a meta-analysis. J Int Neuropsychol Soc. 2007;13(6):920–32.
• Muslimovic D, Post B, Speelman JD, et al. Cognitive decline in Parkinson’s disease: a prospective longitudinal study. J Int Neuropsychol Soc. 2009;15(3):426–37. This is one of the most detailed studies exploring the course of a variety of cognitive domains in PD, including a group followed from time of diagnosis.
Aarsland D, Muniz G, Matthews F. Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord. 2011;26(2):334.
•• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(Pt 11):2958–69. This is the most carefully conducted study of the course and predictors of cognitive decline in a cohort including an incident PD cohort, adding genetic subtyping to the potential demographic and clinical predictors.
Bangen KJ, Jak AJ, Schiehser DM, et al. Complex activities of daily living vary by mild cognitive impairment subtype. J Int Neuropsychol Soc. 2010;16(4):630–9.
Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol. 2005;18(3):149–54.
Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21(8):1123–30.
• Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8. Although not including MCI subjects, this is the first study demonstrating efficacy of memantine for patients with Lewy body dementia.
van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther. 2010. doi: 10.1111/j.1755-5949.1010.00166.x .
• Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–55. This is the first study suggesting that a noradrenergic drug may improve cognition in non-demented PD patients, although cognition was not the primary outcome measure.
Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–45.
Mamikonyan E, Moberg PJ, Siderowf A, et al. Mild cognitive impairment is common in Parkinson’s disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord. 2009;15(3):226–31.